

Hidradenitis Suppurativa Market - 2022

<https://marketpublishers.com/r/H390C8AB85C3EN.html>

Date: October 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: H390C8AB85C3EN

Abstracts

The Hidradenitis Suppurativa Market was valued at USD 725.6 million in 2022 and is anticipated to reach by , at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hidradenitis Suppurativa Market.

This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Hidradenitis Suppurativa Market Scope:

By Clinical Stage

Hurley Stage 1

Hurley Stage 2

Hurley Stage 3

By Skin Condition

Folliculitis

Pimples

Boils

Deep-Acne

Others

By Treatment Type

Surgery

Medications

Photodynamic Therapy (PDT)

Laser Treatment

Others

By Route of Administration

Oral

Parenteral

Others

By End-user

Hospitals

Specialty Clinics

Homecare

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Key Players

Pfizer Inc.

Eli Lilly and Company

AbbVie Inc.

UCB S.A.

Incyte Corporation

Novartis AG

Boehringer Ingelheim

Aclaris Therapeutics, Inc.

InflaRx N.V.

Moonlake Immunotherapeutics

Major Highlights

This report delivers a comprehensive overview of the Hidradenitis Suppurativa Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hidradenitis Suppurativa Market. The Hidradenitis Suppurativa Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Clinical Stage
- 3.2. Snippet by Skin Condition
- 3.3. Snippet by Treatment Type
- 3.4. Snippet by Route of Administration
- 3.5. Snippet by Distribution Channel
- 3.6. Snippet by End-user
- 3.7. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of hidradenitis suppurativa
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with the treatment
 - 4.1.3. Opportunity
 - 4.1.3.1. Increasing research and development activities
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19
 - 6.1.2. Scenario During COVID-19
 - 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY CLINICAL STAGE

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Stage
 - 9.1.2. Market Attractiveness Index, By Clinical Stage
- 9.2. Hurley Stage 1*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Hurley Stage
- 9.4. Hurley Stage

10. BY SKIN CONDITION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
 - 10.1.2. Market Attractiveness Index, By Skin Condition
- 10.2. Folliculitis*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Pimples
- 10.4. Boils
- 10.5. Deep-Acne
- 10.6. Others

11. BY TREATMENT TYPE

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11.1.2. Market Attractiveness Index, By Treatment Type

11.2. Surgery*

11.2.1. Introduction

11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.3. Medications

11.3.1. Biologics

11.3.2. Antibiotics

11.3.3. Hormonal Therapy

11.3.4. Immunosuppressive Drugs

11.3.5. Zinc Supplements

11.3.6. Retinoids

11.3.7. Pain Medication

11.4. Photodynamic Therapy (PDT)

11.5. Laser Treatment

11.6. Others

12. BY ROUTE OF ADMINISTRATION

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

12.1.2. Market Attractiveness Index, By Route of Administration

12.2. Oral*

12.2.1. Introduction

12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

12.3. Parenteral

12.4. Others

13. BY END-USER

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13.1.2. Market Attractiveness Index, By End-user

13.2. Hospitals*

13.2.1. Introduction

13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

- 13.3. Specialty Clinics
- 13.4. Homecare
- 13.5. Others

14. BY DISTRIBUTION CHANNEL

- 14.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.2. Market Attractiveness Index, By Distribution Channel
- 14.3. Hospital Pharmacy*
 - 14.3.1. Introduction
 - 14.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 14.4. Retail Pharmacy
- 14.5. Online Pharmacy
- 14.6. Others

15. BY REGION

- 15.1. Introduction
 - 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 15.1.2. Market Attractiveness Index, By Region
- 15.2. North America
 - 15.2.1. Introduction
 - 15.2.2. Key Region-Specific Dynamics
 - 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
 - 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
 - 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.2.9.1. The U.S.
 - 15.2.9.2. Canada
 - 15.2.9.3. Mexico
- 15.3. Europe
 - 15.3.1. Introduction
 - 15.3.2. Key Region-Specific Dynamics
 - 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
 - 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition

- 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.3.9.1. Germany
 - 15.3.9.2. The U.K.
 - 15.3.9.3. France
 - 15.3.9.4. Italy
 - 15.3.9.5. Spain
 - 15.3.9.6. Rest of Europe
- 15.4. South America
 - 15.4.1. Introduction
 - 15.4.2. Key Region-Specific Dynamics
 - 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
 - 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
 - 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.4.9.1. Brazil
 - 15.4.9.2. Argentina
 - 15.4.9.3. Rest of South America
- 15.5. Asia-Pacific
 - 15.5.1. Introduction
 - 15.5.2. Key Region-Specific Dynamics
 - 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
 - 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
 - 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.5.9.1. China
 - 15.5.9.2. India

15.5.9.3. Japan

15.5.9.4. Australia

15.5.9.5. Rest of Asia-Pacific

15.6. Middle East and Africa

15.6.1. Introduction

15.6.2. Key Region-Specific Dynamics

15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage

15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition

15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. COMPETITIVE LANDSCAPE

16.1. Competitive Scenario

16.2. Product Benchmarking

16.3. Company Share Analysis

16.4. Key Developments and Strategies

17. COMPANY PROFILES

17.1. Pfizer Inc.*

17.1.1. Company Overview

17.1.2. Product Portfolio and Description

17.1.3. Financial Overview

17.1.4. Key Developments

17.2. Eli Lilly and Company

17.3. AbbVie Inc.

17.4. UCB S.A.

17.5. Incyte Corporation

17.6. Novartis AG

17.7. Boehringer Ingelheim

17.8. Aclaris Therapeutics, Inc.

17.9. InflaRx N.V.

17.10. Moonlake Immunotherapeutics (*LIST NOT EXHAUSTIVE)

18. APPENDIX

18.1. About Us and Services

18.2. Contact Us

I would like to order

Product name: Hidradenitis Suppurativa Market - 2022

Product link: <https://marketpublishers.com/r/H390C8AB85C3EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H390C8AB85C3EN.html>